President Trump's approval ratings in April 2026 are in the low 40s, driven by economic concerns and foreign policy.
MSN: US tariffs likely to moderate India Inc's rating profile in H2 FY26; Iran war span key to outlook
US tariffs likely to moderate India Inc's rating profile in H2 FY26; Iran war span key to outlook
Seeking Alpha: Unicycive: 'Buy' Rating On NDA Resubmission OLC And Potential Best-In-Class Profile
I'm initiating Unicycive Therapeutics (UNCY) with a "Buy" rating, and this is based on its ability to have its resubmission of its New Drug Application [NDA] for oxylanthanum carbonate [OLC] accepted ...